Processa Pharmaceuticals, Inc. Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Processa Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2026-06-30 was $92.11K, a 54.68% decline year-over-year.
- Processa Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2026-03-31 was $95.96K, a 57.86% decline year-over-year.
- Processa Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2025-09-30 was $303.05K, a 96.54% increase year-over-year.
- Processa Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, after forfeiture for the quarter ending 2025-06-30 was $203.25K, a 33.16% increase year-over-year.
- Processa Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2025 was $857.55K, a 36.22% increase from fiscal 2024.
- Processa Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2024 was $629.51K, a 40.63% decline from fiscal 2023.
- Processa Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2023 was $1.06M, a 88.15% decline from fiscal 2022.
- Processa Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, after forfeiture for fiscal 2022 was $8.95M, a 172.16% increase from fiscal 2021.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 12 month |
|---|---|---|
| 2026-06-30 | $92.11K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $95.96K 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $857.55K 10-K · filed 2026-03-18 | |
| 2025-09-30 | $303.05K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $203.25K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $227.71K 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $629.51K 10-K · filed 2026-03-18 | |
| 2024-09-30 | $154.19K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $152.63K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $167.64K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $1.06M 10-K · filed 2025-03-20 | |
| 2023-06-30 | $319.12K 10-Q · filed 2024-10-30 | |
| 2023-03-31 | $341.50K 10-Q · filed 2024-10-30 | |
| 2022-12-31 | $8.95M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $3.21M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $2.01M 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $828.90K 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $3.29M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $981.87K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $762.60K 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $620.59K 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |